Trademark: 87366778
Word
PRECIGEN THERAPEUTICS
Status Date
Monday, November 28, 2022
Filing Date
Friday, March 10, 2017
Published for Opposition
Tuesday, August 27, 2019
Abandoned Date
Monday, November 28, 2022
5 Chemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; biochemical preparations for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; chemical reagents for medical and veterinary purposes, namely, for gene and cell therapy for treating genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders
1 Chemicals, biochemicals and reagents for use in industry and science; chemicals, biochemicals and reagents, namely, proteins for regulating, modifying or restricting gene expression; kits consisting primarily of proteins for regulating, modifying or restricting gene expression
45 Technology transfer services, namely, licensing of intellectual property
44 Medical services; Medical services, namely, genetic engineering, biopharmaceuticals and gene therapy services; Healthcare services, namely, treatment of patients with genetic disorders, cancers, rare diseases, infectious diseases, and cardiovascular and immunological diseases and disorders; Medical services, namely, providing medical therapy treatments which are under development or have completed development for patients in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular diseases
42 Scientific research and development services in the field of medicine, pharmacology, immunology, biochemistry, cell biology, genetics, microbiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncology, rare diseases, metabolic disorders, infectious diseases, ophthalmology, and cardiovascular disease which are under development or have completed development; Development of products being genetic therapies, biopharmaceuticals, and effectors to regulate, modulate, and characterize disease states; Development of tools in the nature of software and biotechnological processes to regulate, modulate, and characterize disease states; Research and development services for others in the field of biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use; Research and development services for others in the fields of genetics and biotechnology, namely, genetically engineering DNA, biological organisms, cells, viruses, pathogens, and special purpose cells for scientific, research, medical and laboratory use
Feb 7, 2024
Assignment Of Ownership Not Updated Automatically
Feb 7, 2024
Assignment Of Ownership Not Updated Automatically
Nov 28, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Nov 28, 2022
Abandonment - No Use Statement Filed
May 31, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
May 31, 2022
Teas Change Of Correspondence Received
May 31, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
May 31, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 31, 2022
Teas Change Of Owner Address Received
Apr 13, 2022
Notice Of Approval Of Extension Request E-Mailed
Apr 12, 2022
Sou Extension 5 Granted
Apr 8, 2022
Sou Extension 5 Filed
Apr 8, 2022
Sou Teas Extension Received
Oct 22, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 20, 2021
Sou Extension 4 Granted
Oct 20, 2021
Sou Extension 4 Filed
Oct 20, 2021
Sou Teas Extension Received
Apr 22, 2021
Notice Of Approval Of Extension Request E-Mailed
Apr 20, 2021
Sou Extension 3 Granted
Apr 20, 2021
Sou Extension 3 Filed
Apr 20, 2021
Sou Teas Extension Received
Oct 17, 2020
Notice Of Approval Of Extension Request E-Mailed
Oct 15, 2020
Sou Extension 2 Granted
Oct 15, 2020
Sou Extension 2 Filed
Oct 15, 2020
Sou Teas Extension Received
Apr 11, 2020
Notice Of Approval Of Extension Request E-Mailed
Apr 10, 2020
Sou Extension 1 Granted
Apr 8, 2020
Sou Extension 1 Filed
Apr 10, 2020
Case Assigned To Intent To Use Paralegal
Apr 8, 2020
Sou Teas Extension Received
Apr 8, 2020
Automatic Update Of Assignment Of Ownership
Oct 22, 2019
Noa E-Mailed - Sou Required From Applicant
Aug 27, 2019
Official Gazette Publication Confirmation E-Mailed
Aug 27, 2019
Published For Opposition
Aug 7, 2019
Notification Of Notice Of Publication E-Mailed
Jul 19, 2019
Assigned To Lie
Jul 10, 2019
Approved For Pub - Principal Register
Dec 21, 2018
Report Completed Suspension Check Case Still Suspended
Jun 21, 2018
Report Completed Suspension Check Case Still Suspended
Dec 21, 2017
Notification Of Letter Of Suspension E-Mailed
Dec 21, 2017
Letter Of Suspension E-Mailed
Dec 21, 2017
Suspension Letter Written
Dec 6, 2017
Teas/Email Correspondence Entered
Dec 5, 2017
Correspondence Received In Law Office
Dec 5, 2017
Teas Response To Office Action Received
Jun 5, 2017
Notification Of Non-Final Action E-Mailed
Jun 5, 2017
Non-Final Action E-Mailed
Jun 5, 2017
Non-Final Action Written
Jun 5, 2017
Assigned To Examiner
Mar 16, 2017
New Application Office Supplied Data Entered
Mar 14, 2017
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
